Related Experiment Video
Updated: May 16, 2025
16:57
MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
Published on: February 14, 2012
25.9K
Plasma miRNA Biomarker Signatures in Parkinsonian Syndromes
Stylianos Ravanidis1, Anastasia Bougea1,2, Christos Koros2
1Center of Basic Research, Biomedical Research Foundation of the Academy of Athens, 11527, Athens, Greece.
Molecular Neurobiology
|April 4, 2025
Summary
Plasma microRNAs (miRNAs) show distinct patterns in atypical parkinsonian syndromes (APS), offering potential biomarkers for diagnosis. These brain-enriched molecules may help differentiate conditions like Parkinson's disease and multiple system atrophy.
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- Diagnosing atypical parkinsonian syndromes (APS) is difficult due to similar symptoms and lack of specific tests.
- Brain-enriched microRNAs (miRNAs) in plasma are potential biomarkers for neurological disorders.
Purpose of the Study:
- To identify plasma brain-enriched miRNAs that differentiate APS.
- To explore the molecular pathways affected in these conditions.
Main Methods:
- Prospective study analyzing plasma samples from patients with idiopathic Parkinson's disease (iPD), multiple system atrophy (MSA subtypes), progressive supranuclear palsy (PSP), and controls.
- Reverse transcription-quantitative PCR (RT-qPCR) for miRNA expression analysis.
- Bioinformatic pathway analysis.
Main Results:
- Distinct plasma miRNA expression profiles were found for iPD, MSA, and PSP.
- Opposite miRNA expression trends between MSA and iPD compared to controls suggest different disease mechanisms.
- Dysregulated miRNAs were enriched at chromosome 14q32 and targeted specific transcription factors.
- Enriched pathways included prion diseases, Hippo signaling, TGF-beta signaling, and FoxO signaling.
Conclusions:
- Plasma brain-enriched miRNAs can serve as diagnostic biomarkers for distinguishing between atypical parkinsonian syndromes.
- These findings provide insights into the distinct molecular pathologies underlying different parkinsonian disorders.
Keywords:
BiomarkersDiagnosisMicroRNA (miRNA)Multiple system atrophy (MSA)Parkinson’s disease (PD)PlasmaProgressive supranuclear palsy (PSP)More Related Videos
Related Concept Videos
01:37Neural Regulation
39.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.0K
01:24Parkinson's Disease: Treatment
162
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
162
01:15Parkinson's Disease: Overview
353
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
353